Priya Rastogi

Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial.

Bingshu E. Chen, T. Whelan, K. Gelmon, 2022, JAMA.

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.

G. Hortobagyi, L. Pusztai, D. Tripathy, 2021, The New England journal of medicine.

Abstract GS1-08: CCTGMA.32, a phase III randomized double-blind placebo controlled adjuvant trial of metformin (MET) vs placebo (PLAC) in early breast cancer (BC): Results of the primary efficacy analysis (clinical trials.gov NCT01101438)

Bingshu E. Chen, T. Whelan, K. Gelmon, 2022, Cancer Research.

Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer - Authors' reply.

N. Harbeck, J. O’Shaughnessy, S. Tolaney, 2023, The Lancet. Oncology.

Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–Human Epidermal Growth Factor Receptor 2 Therapy

A. Schneeweiss, R. Gelber, M. Buyse, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial

E. Perez, S. Paik, C. Geyer, 2023, Frontiers in Oncology.

Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

A. Schneeweiss, R. Gelber, M. Buyse, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer

Bingshu E. Chen, K. Gelmon, W. Parulekar, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.